NEW YORK (GenomeWeb News) – Foundation Medicine has filed with the US Securities and Exchange Commission to sell up to $150 million of its common stock in a public offering.

In a Form S-1 filed with the SEC on Thursday, the Cambridge, Mass.-based firm said the "purpose of this offering is to increase our financial flexibility," and proceeds will be used to accelerate its commercial operations and R&D, as well as to expand its technology infrastructure and technology platform, and to fund ongoing and new clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.